ACTU (Actuate Therapeutics) Insider Ownership: 1.16 % (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.45
View Full Analysis

What is Actuate Therapeutics Insider Ownership?

Actuate Therapeutics ACTU -13.25% 14 Insider Ownership is 1.16 % as of Jul. 19, 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Actuate Therapeutics's insider ownership is 1.16%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Actuate Therapeutics's Institutional Ownership is 60.16%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Actuate Therapeutics's Float Percentage Of Total Shares Outstanding is 43.77%.

Actuate Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Insider Ownership Chart

Actuate Therapeutics Historical Data

The historical data trend for Actuate Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 0.65 0.65 0.61 0.55 0.55 0.55 0.55 1.19 1.16 1.16
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.16 % mean?
Actuate Therapeutics (ACTU) has a Insider Ownership of 1.16 % as of Jul. 19, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Insider Ownership too high?
Actuate Therapeutics' current Insider Ownership is 1.16 %. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Insider Ownership compare to RNXT and ESLA?
Actuate Therapeutics' Insider Ownership of 1.16 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Insider Ownership is 1.16 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Insider Ownership of 1.16 %. The current Insider Ownership is 1.16 %. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Insider Ownership is 1.16 % as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.45
Price